Archiv
Dgap-News: Artemis Pharmaceuticals english

Artemis Pharmaceuticals and Regeneron Pharmaceuticals sign Licensing Agreement

Artemis Pharmaceuticals and Regeneron Pharmaceuticals sign Licensing Agreement

Corporate-news announcement processed and sent by Dgap. The sender is solely responsible for the contents of this announcement. --------------------------------------------------------------------------------

Artemis Pharmaceuticals and Regeneron Pharmaceuticals sign Licensing Agreement

Cologne, August 9, 2004 - Artemis Pharmaceuticals Gmbh, Cologne, and Regeneron Pharmaceuticals, Inc., (Nasdaq: Regn), Tarrytown, New York, have signed an agreement under which Artemis grants to Regeneron a non-exclusive sublicense to use, for internal research purposes, its patented gene switch technology based on ligand regulated DNA recombination.

The technology allows very specific and tightly regulated temporal control of gene expression in adult mice and has gained a wide range of acceptance for both academic and industrial usage during the last few years. Inducible gene inactivation represents an optimal method for studying the biological function of selected genes, including those related to human diseases, in specific tissues and organs of the animals. Therefore it provides a powerful basis for drug target validation and the development of new therapeutic products.

Financial terms of the transaction are not being disclosed.

About Artemis: Artemis Pharmaceuticals has developed an exceptionally efficient and powerful technology basis for the identification and validation of disease related genes. The Artemice(TM) Speed platform provides the company with a leading technology position with regard to the efficient, rapid production of complex genetically modified mouse models. Artemice(TM) technology enables the mouse gene to be completely replaced by its human orthologe. These "humanized mice" can play a potentially important role in drug discovery by providing an optimal model for the early in vivo testing of lead compound toxicity and efficacy on the specific human target. When combined with shrnai the Artemice(TM) technology provides a rapid and efficient way to knock down gene expression in all tissues of the mouse in vivo. Artemis cooperates with Merck, Inc., Aventis, Bayer AG, Biovitrum AB, Evotec Neurosciences, Exelixis, Inc., the German Cancer Research Center (Dkfz) and others. Artemis is a wholly owned subsidiary of Exelixis Inc., South San Francisco, CA, USA. Website at http://www.artemispharma.de .

About Regeneron Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer and eye diseases, rheumatoid arthritis and other inflammatory conditions, asthma, and obesity and has preclinical programs in other diseases and disorders. Regeneron corporate headquarters are in Tarrytown, NY. For more information, please visit http://www.regn.com .

For further information please contact

Artemis: Monika Hahn Tel: +49(0)221-96453-10 Mail: m.hahn@artemispharma.de

Regeneron: Investors: Media: Charles Poole Lauren Tortorete Tel: 001-914-345-7641 Tel: 001-212-845-5609 Mail: charles.poole@regeneron.com Mail: ltortorete@biosector2.com

end of message, (c)Dgap 09.08.2004 -------------------------------------------------------------------------------- WKN: ; Isin: Xf000dgap009; Index: Listed:

Serviceangebote
Zur Startseite
-0%1%2%3%4%5%6%7%8%9%10%11%12%13%14%15%16%17%18%19%20%21%22%23%24%25%26%27%28%29%30%31%32%33%34%35%36%37%38%39%40%41%42%43%44%45%46%47%48%49%50%51%52%53%54%55%56%57%58%59%60%61%62%63%64%65%66%67%68%69%70%71%72%73%74%75%76%77%78%79%80%81%82%83%84%85%86%87%88%89%90%91%92%93%94%95%96%97%98%99%100%